Polynova Cardiovascular

Polynova Cardiovascular is developing a novel heart valve replacement technology using state-of-the-art synthetic biomaterials, aiming to replace existing animal tissue products used in transcatheter aortic valve replacement (TAVR) procedures, thereby avoiding open-heart surgery. Polynova's goal is to become the first company to commercialize a safe and effective polymer-based artificial heart valve.